Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Biomedical Advanced Research and Development Authority (BARDA) has granted $2.9m to Avaxia Biologics to conduct R&D for an antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident.
Subscribe to our email newsletter
The contract allows Avaxia Biologics to complete the pre-clinical pharmacology studies for oral antibody therapy.
Avaxia CEO Barbara Fox said they look forward to working with BARDA to develop a novel drug that can effectively protect the gastrointestinal tract from radiation damage.
"Besides providing the company with additional scientific infrastructure, the research to be conducted on this therapeutic will contribute to and support our innovative technology platform and bolster work being done in the related field of inflammatory bowel disease," Fox said